{"id":"rsv-polyclonal-immunoglobulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This product is a polyclonal antibody preparation derived from human plasma of donors with high titers of RSV-specific antibodies. When administered intravenously, these antibodies directly bind to RSV surface proteins, preventing viral attachment and entry into host cells, thereby reducing viral replication and disease severity. This passive immunization approach provides immediate but temporary protection, particularly in high-risk populations.","oneSentence":"RSV polyclonal immunoglobulin provides passive immunity by supplying antibodies that bind to respiratory syncytial virus and neutralize its infectivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:26.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of serious lower respiratory tract RSV infection in high-risk infants and young children (including premature infants and those with congenital heart disease or chronic lung disease)"}]},"trialDetails":[{"nctId":"NCT00001903","phase":"PHASE4","title":"Prevention of RSV Infections in Bone Marrow Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-04","conditions":"Respiratory Syncytial Virus Infection","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"RSV Polyclonal Immunoglobulin","genericName":"RSV Polyclonal Immunoglobulin","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RSV Polyclonal Immunoglobulin is used to prevent Respiratory Syncytial Virus Infections in specific populations, such as bone marrow transplant recipients. It is a replacement therapy with immunomodulatory effects, although its exact modality is unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}